The latest drug alerts to come in are on Avandia, Fosomax, Boniva, Actonel, Reclast, and the anti-psychotic drug, Seroquel. The ambulance chasers are burning up the internet looking for the hapless victims of these overly marketed drugs.
Avandia, an FDA approved drug for type 2 diabetes has generated a 30% to 40% increased risk of heart attack in those taking them short term (6 months). If you are taking Avandia now, discuss this with your doctor immediately. And if your doctor isn't aware of this, direct him to the FDA, which has received a pooled study from the manufacturers attesting to this.
The bisphosponates (Fosomax, Boniva, Actonel, and Reclast), increase the odds of those taking these drugs to develop atrial fibrillation. This is an erratic and sometimes life threatening heart rhythm that often produces blood clots and other complications.
And the very latest warning cites Seroguel, an anti-psychotic drug. Astra-Zeneca, the maker of the drug is currently being sued in the U.S. by nearly 10,000 users. This overly promoted drug is producing severe weight gain and diabetes.
And what is the FDA doing about all this? I'll bet you've already guessed. You're right. Nothing! Perhaps they're afraid of the American Bar Association, whose members are having a really great time with all all these lawsuits, active and pending. It seems that the FDA is afraid of everyone except us beleaguered taxpayers who have to foot the bill for their inaction anyway.
One of the sorry facts of life is that no one needs to take Fosomax or any of the other bisphosphonate drugs. There are excellent natural supplement formulations out there that work at least as well, without the formidable negative side effects. And if you think the side effects are not formidable, try getting a tooth implant after you've been on one of these bisphosphonates for a while.
You can find counsel, commentary, and links to reliable supplement manufacturers at LeQuadrillage.com No fantastic claims made here, just solid, unbiased information
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment